Treatment of extensively drug-resistant tuberculosis/Authors' reply

Questions about the best drug combinations and doses for XDR-TB highlight the urgent need for clinical trials to optimise current treatment approaches.4 Indeed, scientists and activists have called attention to this need.5 Jussara Silva and colleagues raise the crucial question of whether treatment duration itself should be regarded as an exposure variable in the multivariable model used in our analysis.